A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2010 |
| End Date: | December 2015 |
A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma
In this study, a new chemotherapeutic agent, panitumumab, will be tested in combination with
another chemotherapeutic drug, capecitabine, along with external radiotherapy, to find out
whether this combination is effective and safe to use before surgery.
Surgical resection remains the standard procedure for patients with localized resectable
pancreatic cancer.
Neoadjuvant or preoperative therapy with chemotherapy and radiation therapy has been
proposed as an alternative approach in patients with localized pancreatic adenocarcinoma.
Advantages are: 1) early start of systemic therapy targeting micrometastatic disease; 2)
increased compliance with chemoradiotherapy; 3) increase primary tumor complete resection
rates; 4) avoidance of surgery in patients with rapidly developing metastatic disease; and
5) importantly, it provides an important resource for research in terms of tissue
acquisition before and after therapy . Finally, this is an opportunity to test the safety
and efficacy of a novel combination of weekly panitumumab, oral capecitabine and radiation
in pancreatic cancer.
We found this trial at
1
site
Umass Memorial Medical Center UMass Memorial Medical Center is the region's trusted academic medical center,...
Click here to add this to my saved trials
